ATE366324T1 - Inhibierung eines fgf-bindungsproteins durch ribozyme - Google Patents

Inhibierung eines fgf-bindungsproteins durch ribozyme

Info

Publication number
ATE366324T1
ATE366324T1 AT98950713T AT98950713T ATE366324T1 AT E366324 T1 ATE366324 T1 AT E366324T1 AT 98950713 T AT98950713 T AT 98950713T AT 98950713 T AT98950713 T AT 98950713T AT E366324 T1 ATE366324 T1 AT E366324T1
Authority
AT
Austria
Prior art keywords
fgf
ribozymes
binding protein
mrna
found
Prior art date
Application number
AT98950713T
Other languages
English (en)
Inventor
Anton Wellstein
Frank Czubayko
Original Assignee
Univ Georgetown
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Georgetown filed Critical Univ Georgetown
Application granted granted Critical
Publication of ATE366324T1 publication Critical patent/ATE366324T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT98950713T 1997-09-26 1998-09-25 Inhibierung eines fgf-bindungsproteins durch ribozyme ATE366324T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6017097P 1997-09-26 1997-09-26

Publications (1)

Publication Number Publication Date
ATE366324T1 true ATE366324T1 (de) 2007-07-15

Family

ID=22027820

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98950713T ATE366324T1 (de) 1997-09-26 1998-09-25 Inhibierung eines fgf-bindungsproteins durch ribozyme

Country Status (8)

Country Link
US (1) US6245748B1 (de)
EP (1) EP1034301B1 (de)
JP (1) JP2001517461A (de)
AT (1) ATE366324T1 (de)
AU (1) AU9669498A (de)
CA (1) CA2304987C (de)
DE (1) DE69838035D1 (de)
WO (1) WO1999015703A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19956568A1 (de) * 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
US7829693B2 (en) * 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
US8546143B2 (en) 2001-01-09 2013-10-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene

Also Published As

Publication number Publication date
JP2001517461A (ja) 2001-10-09
EP1034301A1 (de) 2000-09-13
EP1034301A4 (de) 2005-04-06
CA2304987A1 (en) 1999-04-01
DE69838035D1 (de) 2007-08-16
US6245748B1 (en) 2001-06-12
EP1034301B1 (de) 2007-07-04
WO1999015703A1 (en) 1999-04-01
AU9669498A (en) 1999-04-12
CA2304987C (en) 2005-05-17

Similar Documents

Publication Publication Date Title
GB9504265D0 (en) Corticosteroid-containing pharmaceutical composition
ATE338563T1 (de) Verfahren zur behandlung von patienten die unter multipler sklerose leiden mit konsensus- interferon
PT1011682E (pt) Contraceptivo hormonal
DK0814831T3 (da) Medikamenter til behandling af autoimmune sygdomme under anvendelse af interferon-tau
DE69315847D1 (de) Verfahren zur behandlung einer durch lfa-1 vermittelten störung
DE69502281D1 (de) Verminderung der hautreizung während einer iontophoretischen abgabe von medikamenten
ES2086301T3 (es) Inhibicion de una oclusion trombotica arterial o tromboembolismo.
ATE231500T1 (de) Hydroxymatairesinol in der krebs-prevention
PT1098643E (pt) Fenilacetilglutamina fenilacetilisoglutamina e/ou fenilacetato para o tratamento de doencas neoplasicas
ATE226014T1 (de) Prophylaktische behandlung der allergischen kontaktdermatitis
ATE245452T1 (de) Hyaluronatlyase als penetrationsförderer in topischen mitteln
DE60017878D1 (de) Kombinationspräparate zur behandlung von erkrankungen, die mit angiogenese verbunden sind
DK1407784T3 (da) Antitumormidler
DE69824164D1 (de) Arzneizubereitungen zur behandlung sexueller funktionsstörungen
ATE366324T1 (de) Inhibierung eines fgf-bindungsproteins durch ribozyme
DE69811931D1 (de) Mri-mittel für die verabreichung von therapeutischen mitteln
DE69533311D1 (de) Verfahren zur behandlung von autoimmunerkrankungen mittels typ-1-interferonen
DE69636550D1 (de) Verrieglungskupplungen für osmotische abgabevorrichtungen
DK1194109T3 (da) Topiske formuleringer omfattende hud-gennemtrængningsmidler samt anvendelse deraf
FR2389409A1 (de)
PT1150703E (pt) Terapia de esclerose multipla com chaperonina 10 e beta-interferao
AR059965A2 (es) Uso de 8,9-dehidroestrona para la preparacion de un medicamento antioxidante
DE60132436D1 (de) Retinolsäure-rezeptor beta-2 und gentherapievektoren für die behandlung von neurologischen erkrankungen
DE60035504D1 (de) Verfahren für die verabreichung von heilmitteln mittels einer dextrinlösung
Nelson et al. Effects of inhibitors of tumor promotion on 12-O-tetradecanoylphor-bol-13-acetate-induced keratin modification in mouse epidermis

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties